Sunshine Biopharma Inc
NASDAQ:SBFM

Watchlist Manager
Sunshine Biopharma Inc Logo
Sunshine Biopharma Inc
NASDAQ:SBFM
Watchlist
Price: 1.31 USD -5.07% Market Closed
Market Cap: 6.4m USD

Wall Street
Price Targets

SBFM Price Targets Summary
Sunshine Biopharma Inc

Wall Street analysts forecast SBFM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBFM is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.

Lowest
Price Target
6.06 USD
363% Upside
Average
Price Target
6.12 USD
367% Upside
Highest
Price Target
6.3 USD
381% Upside
Sunshine Biopharma Inc Competitors:
Price Targets
PHARM
Pharming Group NV
45% Upside
GNFT
Genfit SA
71% Upside
VYGR
Voyager Therapeutics Inc
278% Upside
FOLD
Amicus Therapeutics Inc
14% Upside
ZNTL
Zentalis Pharmaceuticals Inc
301% Upside
ABNX
Abionyx Pharma SA
214% Upside
CHRS
Coherus BioSciences Inc
322% Upside
IMMU
Mendus AB (publ)
227% Upside

Revenue
Forecast

Revenue Estimate
Sunshine Biopharma Inc

The compound annual growth rate of Sunshine Biopharma Inc's revenue for the next 2 years is 21%.

N/A
Past Growth
21%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Sunshine Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Sunshine Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SBFM's stock price target?
Price Target
6.12 USD

According to Wall Street analysts, the average 1-year price target for SBFM is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.

What is Sunshine Biopharma Inc's Revenue forecast?
Projected CAGR
21%

The compound annual growth rate of Sunshine Biopharma Inc's revenue for the next 2 years is 21%.

Back to Top